Insight Molecular Diagnostics (IMDX) Assets (2015 - 2026)

Insight Molecular Diagnostics (IMDX) has 12 years of Assets data on file, last reported at $40.4 million in Q1 2026.

• Quarterly Assets fell 33.02% year-over-year to $40.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.4 million (down 33.02% YoY) and the FY2025 annual result came in at $25.8 million, down 26.58% from the prior year.
• Assets improved to $40.4 million in Q1 2026 per IMDX's latest filing, from $25.8 million in the prior quarter.
• The five-year high for Assets was $171.1 million in Q2 2022, with the low at $25.8 million in Q4 2025.
• Average Assets over 5 years is $80.8 million, with a median of $74.7 million recorded in 2024.
• Year-over-year, Assets gained 13.12% in 2022 and plunged 53.16% in 2024.
• Insight Molecular Diagnostics' Assets stood at $100.1 million in 2022, then declined by 25.18% to $74.9 million in 2023, then sank by 53.16% to $35.1 million in 2024, then retreated by 26.58% to $25.8 million in 2025, then jumped by 56.96% to $40.4 million in 2026.
• Business Quant data shows IMDX's Assets at $40.4 million in Q1 2026, $25.8 million in Q4 2025, and $43.9 million in Q3 2025.